Search Results

Our CSO, Maria, has recently traveled to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , a conference organized by both the EFMC and the ACSMEDI, in an effort to share the most novel medicinal chemistry advancements in both the US and Europe. Another section was dedicated to Chemistry Tools, highlighting their importance. This Chemistry Tools session was more industry focused than those before, and Maria shared the floor

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry

October 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic potential. Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopoeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical application due to unfavourable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to 'drug-like' properties and a few such compounds have now undergone clinical trial. We review the current state of CB2 ligand development and progress in optimising physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds." Read more at the source #DrGPCR #GPCR #IndustryNews

Home → Flash News → Started in medicinal chemistry. Got hooked on ligand design. Dr. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen GPCR Podcast Started in medicinal chemistry. Got hooked on ligand design. Dr. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen

He subsequently returned to Munich as a research associate at the Institute of Pharmaceutical Chemistry Habilitus, he was appointed at the University of Bonn as a Professor of Pharmaceutical Chemistry declining Peter has been chaired Full Professor of Pharmaceutical / Medicinal Chemistry at the Friedrich-Alexander University Erlangen-Nürnberg and declined an offer for the Chair for Pharmaceutical Chemistry at the Peter Gmeiner has been spokesman of the Research Training Group "Medicinal Chemistry of Selective GPCR

Antonella trained as a medicinal chemist in Italy, followed by a Ph.D. in computational medicinal chemistry